Gómez-Almaguer David, Ruiz-Argüelles Guillermo J, Gutiérrez-Aguirre César H, Jaime-Pérez José C
Servicio de Hematología, Hospital Universitario de la UANL "Dr. José E. González", Monterrey, NL.
Rev Invest Clin. 2005 Mar-Apr;57(2):291-7.
The feasibility of applying allogeneic cell -mediated therapy in conjunction with allogeneic hematopoietic cell transplantation following reduced -intensity conditioning, with minimal toxicity and no serious transplant-related complications, makes it possible to perform such procedures on an outpatient basis as well to offer a valid option for cure to elderly individuals and patients with less than optimal performance status. Based on available experience, clinical application of this innovative therapy may open new horizons for the treatment of patients with leukemia, lymphoma, myeloma and other diseases. Many patients can now benefit from the advantages of immunotherapy mediated by alloreactive donor lymphocytes, while minimizing transplant-related toxicity and mortality. This kind of transplant is making real progress in the world of transplantation.
